AbbVie Enters Into the Obesity Drug Market With a License Agreement
GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
Category: Healthcare & Pharmaceuticals
“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
Based on Results From the Phase 3 BRUIN CLL-321 trial, Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
Merck’s Application for KEYTRUDA® (pembrolizumab) Receives US FDA’s Priority Review
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the [Read More…]
A Rare Side Effect for Cancer Immunotherapy Detected
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
US FDA Approves Ctexli, First Treatment for Cerebrotendinous Xanthomatosis of Mirum Pharma
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
Intriguing New Class of Antimalarial Drugs Discovered
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
The FDA has approved GOMEKLIâ„¢(mirdametinib) for the treatment of NF1-PN in both adult and pediatric patients, according to SpringWorks Therapeutics
The U.S. Food and Drug Administration (FDA) has approved GOMEKLIâ„¢ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with [Read More…]
A Drug Can Avoid Osteoporosis and Muscle Loss After Rapid Weight Loss
Rapid weight reduction might raise the risk of osteoporosis and reduce muscular mass. However, there is now excellent news for those who may be at danger when taking weight loss medications. According to a recent study from Aarhus University, the adverse effects can be mitigated by the medication bimagrumab.
Key to Immunotherapy: A Computer Model Assists in Identifying Immune Cells That Fight Cancer
PD-1 inhibitors and other immune checkpoint inhibitors can be used to treat dozens of different forms of cancer.
